IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancerBusiness Wire • 12/06/24
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancerBusiness Wire • 12/05/24
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trialBusiness Wire • 06/25/24
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trialBusiness Wire • 04/05/24
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancerBusiness Wire • 11/11/22
ION's Gemini™ Enhanced Frequency Source technology awarded Wide Azimuth 3D acquisition contract in the Mediterranean SeaGlobeNewsWire • 05/23/22
NYSE to Suspend Trading Immediately in ION Geophysical Corporation (IO) and Commence Delisting ProceedingsBusiness Wire • 05/18/22
ION completes Colombia Caribe 2D reprocessing program providing enhanced regional understanding of the Caribbean offshoreGlobeNewsWire • 05/03/22
ION Receives Non-compliance Notice from NYSE Regarding 10-K Filing DelinquencyGlobeNewsWire • 04/22/22
ION Commences Voluntary Chapter 11 Process with Lender Support and DIP FinancingGlobeNewsWire • 04/13/22
ION announces agreement for further forbearance extensions related to both its first and second lien debtGlobeNewsWire • 04/11/22
ION announces certain holders of its second priority 2025 notes purchase ION's indebtedness to PNC, agree to further forbearance extensions related to both the first lien and second lien debtGlobeNewsWire • 03/09/22
5 Short Squeeze Candidates To Watch: Kaival Tops The List Again, Oil And Agriculture Stocks Join With Rising PricesBenzinga • 03/07/22
ION announces a continued forbearance and amendment extension related to its revolving credit agreement and forbearance agreement extension related to its senior secured second priority notes due 2025GlobeNewsWire • 02/15/22